News
Metamizole in Pain Management for Patients with Subarachnoid Hemorrhage
A study by Czech authors from the University Hospital St. Anna in Brno, recently published in the British Journal of Neurosurgery, evaluated analgesic treatment in patients with subarachnoid hemorrhage. The use of metamizole as the primary analgesic was associated with a significantly lower risk of adverse clinical outcomes at 2 weeks and 6 months compared to other non-opioid and opioid analgesics.
Comparison of the Effectiveness of Different Types of Toothbrushes in Orthodontic Patients
The aim of the study cited below was to evaluate the efficiency of a manual orthodontic brush, an…
Efficacy and Safety of Ozanimod in the Treatment of Relapsing-Remitting MS
The sphingosine-1-phosphate receptor (S1PR) modulator ozanimod has recently been approved for the…
Ozanimod Expands Treatment Options for Ulcerative Colitis in Adult Patients
As a review article published last year in the journal Drugs suggests, ozanimod is an effective and…
Ozanimod in Induction and Maintenance Therapy for Ulcerative Colitis − True North Study Results
Ozanimod is a selective modulator of the sphingosine-1-phosphate receptor (S1PR) approved for the…
Prognostic Significance of Mutations in Maintenance Hypomethylation Therapy for AML Patients
A recently published sub-analysis of the QUAZAR AML-001 clinical trial evaluated the efficacy of…
Current Recommendations by the ELN Expert Panel on AML Diagnosis Management
The 2022 recommendations from European LeukemiaNet (ELN) add new information to the previous…
Overuse of Corticosteroids as a Serious Problem in ITP
Corticosteroids (CS) are a common part of the treatment for immune thrombocytopenia (ITP). However,…
Romiplostim in Life-Threatening Bleeding Situations − Case Reports
Immune thrombocytopenic purpura, or immune thrombocytopenia (ITP), typically manifests as bleeding…
CYP Enzyme? Cytochrome P450 2D6 and Drug Metabolism
The CYP2D6 isoenzyme of cytochrome P450 participates in the metabolism of approximately 20% of commonly...